Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2014-04-21 | Todd C. Davis(C) Director 2007 53 ... The compensation committee consists of Messrs. Aryeh, Davis (chair) and Knott and Dr. LaMattina. ... Todd Davis(2) 57,000 94,478 149,647 — 301,125 ... (2) As of December 31, 2013, Mr. Davis held options to purchase 30,338 shares of our common stock and 2,925 unvested shares of restricted stock. During 2013, Mr. Davis received 2,925 restricted stock units with a grant date fair value of $94,478 and 7,335 stock options with a grant date fair value of $149,647. Mr. Davis elected to receive 1,393 shares of fully vested stock in lieu of $45,000 of his 2013 cash retainer for his services as a non-employee director. |
| 2015-03-13 | Todd C. Davis(C) - Director, Age 54, Member of the compensation committee (C). Compensation: $264,159 in 2014. |
| 2016-04-12 | Todd C. Davis(C) Director 55 2007 (C) Member of the compensation committee ... Compensation of Directors ... Todd Davis(2) As of December 31, 2015, Mr. Davis held options to purchase 16,734 shares of our common stock and 925 restricted stock units. During 2015, Mr. Davis received 925 restricted stock units with a grant date fair value of $83,019 and 1,426 stock options with a grant date fair value of $127,984. Mr. Davis elected to receive 501 shares of fully vested stock in lieu of $45,000 of his 2015 cash retainer for his services as a non-employee director. ... Cash Fees $15,000 Stock Awards $127,984 Option Awards $139,946 Total $282,930 |
| 2017-04-14 | Todd C. Davis(A)(C) Director 2007 56 ... The audit committee currently consists of Messrs. Davis and Patel and Dr. Sabba (chair). ... The compensation committee consists of Messrs. Aryeh and Davis (chair) and Dr. LaMattina. ... Todd Davis 47,716 96,633 140,557 284,906 ... During 2016, Mr. Davis received 810 restricted stock units with a grant date fair value of $96,633 and 2,329 stock options with a grant date fair value of $140,557. |
| 2018-04-30 | Todd C. Davis(A)(C) Director 2007 57; Member of the audit and compensation committees; 2017 compensation total $283,448. |
| 2019-04-24 | Todd Davis (C) 58 2007 Founder and Managing Partner of RoyaltyRx Capital ... Mr. Davis received 493 restricted stock units with a grant date fair value of $96,584 and 2,474 stock options with a grant date fair value of $186,596. Total: $343,365. |
| 2020-04-24 | Todd C. Davis (C) 59 2007 Founder and Managing Partner of RoyaltyRx Capital ... Mr. Davis’ financial and accounting expertise and his service as a director of public and private companies contributed to our board of directors’ conclusion that he should serve as a director of our company. ... The compensation committee consists of Messrs. Aryeh and Davis (chair) and Dr. LaMattina. ... Todd Davis 65,027 94,848 190,025 349,900 ... (2) As of December 31, 2019, Mr. Davis held options to purchase 9,001 shares of our common stock and 835 restricted stock units. During 2019, Mr. Davis received 835 restricted stock units with a grant date fair value of $94,848 and 4,071 stock options with a grant date fair value of $190,025. |
| 2021-04-23 | Todd C. Davis has served as a member of our board of director since March 2007. He is the Founder and Managing Partner of RoyaltyRx Capital, a special opportunities investment firm founded in 2018. From 2006 until 2018, Mr. Davis was a Founder & Managing Partner of Cowen/HealthCare Royalty Partners, a global healthcare investment firm. He has almost thirty years of experience in both operations and investing in the biopharmaceutical and life science industries. Mr. Davis has been involved in over $3 billion in healthcare financings including growth equity, public equity turnarounds, structured debt and royalty acquisitions. He has also led, structured and closed over 40 additional intellectual property licenses, as well as hybrid royalty-debt deals. Previously, Mr. Davis was a partner at Paul Capital Partners, where he co-managed that firm’s royalty investments as a member of the Royalty Management Committee. He also served as a partner responsible for biopharmaceutical growth equity investments at Apax Partners. Mr. Davis began his business career in sales at Abbott Laboratories where he held several commercial roles of increasing responsibility. He subsequently held general management, business development, and licensing roles at Elan Pharmaceuticals. Mr. Davis is a navy veteran and holds a B.S. from the U.S. Naval Academy and an M.B.A. from Harvard University. He currently serves on the board of Palvella Therapeutics Inc., a privately-held biopharmaceutical company, BioDelivery Sciences International, Inc., a publicly-traded specialty pharmaceutical company, and Vaxart, Inc., a publicly-traded specialty pharmaceutical company. He is also a board member of the Harvard Business School Healthcare Alumni Association. Mr. Davis’ financial and accounting expertise and his service as a director of public and private companies contributed to our board of directors’ conclusion that he should serve as a director of our company. |
| 2022-04-22 | Todd C. Davis has served as a member of our board of directors since March 2007. He is the Founder and Managing Partner of RoyaltyRx Capital. Mr. Davis’ financial and accounting expertise and his service as a director of public and private companies contributed to our board of directors’ conclusion that he should serve as a director of our company. He is a member of the human capital management and compensation committee. Total compensation for 2021 was $327,807. |
| 2023-04-20 | Todd C. Davis is our Chief Executive Officer, a position he has held since December 2022, and has served as a member of the Board since March 2007. Mr. Davis was the Founder and Managing Partner of RoyaltyRx Capital, a special opportunities investment firm founded in 2018. From 2006 until 2018, Mr. Davis was a Founder and Managing Partner of HealthCare Royalty Partners, a global healthcare investment firm which grew from zero to approximately $4 billion in capital commitments during his tenure. Previously, Mr. Davis served as a partner responsible for biopharmaceutical growth equity investments at Apax Partners. Mr. Davis began his business career in sales at Abbott Laboratories where he held several sales and marketing positions of increasing responsibility. Subsequently he led corporate development and held strategic planning and general management responsibilities at Elan Pharmaceuticals. Cumulatively he has almost thirty years of experience in both operations and investing in the biopharmaceutical and life sciences industries. Mr. Davis has been involved in over $3 billion of healthcare financings including growth equity, public equity turnarounds, structured debt and royalty acquisitions. He has also led, structured and closed over 40 additional intellectual property licenses, as well as hybrid royalty-debt transactions. Mr. Davis is a navy combat veteran and holds a B.S. from the U.S. Naval Academy and an M.B.A. from Harvard University. He currently also serves on the boards of Palvella Therapeutics Inc. and ViroCell Biologics – both privately held companies. He is a former board member of the Harvard Business School Healthcare Alumni Association. Mr. Davis’ extensive knowledge of our business, as well as his financial and accounting expertise and his service as a director of public and private companies contributed to the Board’ conclusion that he should serve as a director of our company. |
| 2024-04-25 | Todd C. Davis is our Chief Executive Officer, a position he has held since December 2022, and has served as a member of the Board since March 2007. ... Todd C. Davis, our Chief Executive Officer, received no compensation for his service as a member of the Board for fiscal year 2023. Mr. Davis’ compensation is further described under the section titled “Executive Compensation and Other Information” below. |
| Filing Date | Source Excerpt |
|---|---|
| 2001-04-06 | Todd C. Davis 39 September 1998 Director ... The Company has an Audit Committee composed of independent directors, ... The current independent directors of the Audit Committee are Digby W. Barrios, John M. Bailey, (both appointed in June 1997) and Todd C. Davis (appointed May 2000). |
| 2002-04-30 | Todd C. Davis. Mr. Davis has been a Director of the Company since September 1998. ... The current independent directors of the Audit Committee are Digby W. Barrios, John M. Bailey (both appointed in June 1997), and Todd C. Davis (appointed May 2000). |
Data sourced from SEC filings. Last updated: 2026-02-03